Amgen vs. Novo Nordisk: Which Pharma Giant Is the Better Buy?

The article positions Amgen as a more attractive investment than Novo Nordisk, highlighting Amgen's diversified portfolio, robust pipeline including a promising late-stage obesity drug (MariTide with ~20% weight loss), and superior valuation metrics (14.5x forward P/E, 3.1% dividend yield), despite upcoming patent expirations for Prolia and Xgeva. Conversely, while Novo Nordisk maintains a 54% GLP-1 market share and projects higher 2025 EPS growth of 21%, its investment outlook is tempered by intense competition from Eli Lilly, disappointing CagriSema trial data, and an ongoing CEO transition, contributing to its 22% year-to-date stock decline and higher valuation (15.51x forward P/E).

Analysis

Amgen (AMGN) and Novo Nordisk (NVO) present a classic growth versus value trade-off, with current sentiment favoring Amgen's stability. Amgen's strength lies in its diversified portfolio, bolstered by the Horizon Therapeutics acquisition, and a robust biosimilar pipeline targeting major drugs like Stelara, Eylea, Opdivo, and Keytruda. While its entry into the obesity market with MariTide is promising due to a potential monthly dosing schedule, Phase II data showed weight loss of approximately 20%, which was at the lower end of investor expectations. The company faces a significant headwind with patent expirations for its key drugs Prolia and Xgeva in 2025, which tempers its modest 5% projected 2025 EPS growth. Conversely, Novo Nordisk maintains a dominant 54% market share in the high-growth GLP-1 segment and projects a robust 21% EPS increase for 2025. However, this growth narrative is clouded by several material risks: intense competition from Eli Lilly, disappointing clinical data for its next-generation obesity drug CagriSema, and leadership instability with an impending CEO transition. These factors have contributed to NVO's 22% year-to-date share price decline, and while 2025 EPS estimates are rising, 2026 estimates have been revised downward. From a valuation perspective, Amgen trades at a more favorable 14.5 times forward earnings with a 3.1% dividend yield, compared to Novo Nordisk's 15.51 times multiple and 2.5% yield.

Key Decisions for Investors

• Investors should consider Amgen for its defensive characteristics, including a diversified portfolio, a more attractive valuation at a 14.5x forward P/E, and a superior 3.1% dividend yield, which may offer a more balanced risk profile in the current environment.
• A key risk for Amgen is the 2025 patent cliff for Prolia and Xgeva; therefore, investors must closely monitor the sales trajectory of its growth products and the progress of its late-stage pipeline, particularly the Phase III obesity trials for MariTide, to validate its growth outlook.
• Despite Novo Nordisk’s strong projected 21% EPS growth, investors should be cautious due to significant execution risks, including intensifying competition, underwhelming CagriSema data, and a CEO transition, which have already pressured the stock and may continue to weigh on sentiment.
• For a pair trade, a long AMGN and short NVO position could be considered to capitalize on the diverging fundamentals, valuation metrics, and market sentiment highlighted in the analysis, though NVO's high short interest could create volatility.